Strategic Investment Opportunities in the Booming Clinical Trial Software Market
Nov 2024
| Published in Investors in Healthcare on October 30, 2024.
The clinical trial software market is expanding rapidly, driven by the growing complexity of trials and increasing regulatory demands. Pharmaceutical companies, facing rising R&D costs – estimated at over $2 billion per drug approval – are under pressure to bring treatments to market faster. In this environment, innovative software solutions are essential for streamlining clinical trial operations, reducing costs and accelerating time-to-market. As these solutions demonstrate their value, they also present significant investment opportunities for those looking to place or secure investments in this space. |
Summary
-
Lincoln's experts explore significant investment opportunities in this evolving sector.
- Sign up to receive Lincoln's perspectives
Market Landscape: Growing Demand for Clinical Trial Software
Innovation and technology are transforming the clinical trial landscape in many ways, including by improving patient recruitment through predictive modeling and optimizing data analysis during trials.
Cutting-edge software can now predict patient eligibility, shortening recruitment times by as much as 30%, while machine learning algorithms help identify potential safety concerns earlier. Wearable devices and remote monitoring tools allow real-time data collection without the need for in-person visits, reducing trial durations by up to 20% and decreasing costs by as much as 15%. These improvements offer a clear financial incentive for pharmaceutical companies and contract research organizations to adopt these innovations. Moreover, as decentralized trials grow, clinical trial software will be crucial in expanding access to more diverse patient populations.
Recent trends demonstrate that the global clinical trial management system market is projected to reach $3.5 billion USD by 2030, growing at a compound annual growth rate (CAGR) of 13.6%. This growth is fueled by the rising need for efficient data management and compliance with stringent regulatory standards (most notably in the EU and U.S.), making clinical trial software an attractive area for investment.
Strategies to Maximize Return on Investment in Clinical Trial Software
Companies with strong differentiation, such as specialized software for rare disease trials, regulatory compliance, or partnerships with major pharmaceutical firms, have established a competitive edge. Investors should prioritize firms with unique capabilities that align with market needs. For example, Greenphire, recognized for its industry-leading clinical trial payment solutions, was acquired by private equity firm Thoma Bravo, underscoring its critical role in streamlining financial processes in clinical trials. Similarly, YPrime secured a strategic partnership with Flexpoint Ford, driven by its innovative e-clinical data management solutions, reinforcing its position as a valuable player in the clinical trial software market.
While the clinical trial software market offers several key investment opportunities, private equity investors should focus on four strategic considerations:
| Market Size and Growth Potential: The sector’s significant projected growth offers fertile ground for private equity investment. Recent estimates are that the global clinical trial software market will reach $5.1 billion USD by 2027, emphasizing the growing demand for scalable digital solutions. |
| Scalability of Solutions: As trials grow more complex, software platforms that can scale to manage large volumes of data and adapt to evolving regulatory frameworks are in demand. This scalability ensures long-term viability and attractiveness to pharmaceutical companies. |
| Intellectual Property and Competitive Moats: Companies with strong intellectual property protections and innovative solutions are better positioned for sustainable growth. Investors should seek firms that stand out through technological innovation and a robust intellectual property portfolio. |
| Recurring Revenue Models: Companies that utilize subscription-based models offer more predictable returns than those reliant on project-based revenues. Recurring revenue models provide financial stability and long-term profitability, making these companies more attractive for investments. |
Recent Significant Deals in the Pharma and Healthcare Technology Market
| Target | Cluepoints | Qualifyze | Sensio | Compile | Endpoint Clinical + Fortrea Patient Access |
| Acquirer | EQT | Insight | Nordic Capital | McKesson | Arsenal Capital Partners |
| Date | Jun-24 | Sep-24 | Jul-24 | Jan-24 | Apr-23 |
| Description | CluePoints provides AI-powered software for Risk-Based Quality Management (RBQM) in clinical trials. | Qualifyze specializes in supply chain compliance software for the life sciences industry. | Sensio is a provider of smart monitoring technology for elderly and social care settings. | Compile is a healthcare data platform that aggregates and integrates data from healthcare providers and patients. | Endpoint is a provider of RTSM solutions into pharma, and Fortrea Patient Access is a specialist in HUB services and patient access. |
| Deal size | Undisclosed | $54 million (Series B funding) | Undisclosed | Undisclosed | Undisclosed |
| Geography | Belgium (Target), Sweden (Acquirer) | Germany (Target), U.S. (Acquirer) | Norway (Target), Sweden (Acquirer) | U.S. (Target), U.S. (Acquirer) | U.S. (Target), U.S. (Acquirer) |
Contributors
Meet Professionals with Complementary Expertise in Healthcare
It’s extremely rewarding to work in one of the largest and most diverse global business sectors helping support clients to realize their goals.
Matthew Lee
Managing Director, Head of UK & Co-head of Healthcare, Europe
London
I enjoy working closely with clients to overcome challenging situations and to develop strategies to meet their business goals.
Dirk-Oliver Löffler
Managing Director & Co-head of Healthcare, Europe
Frankfurt
My goal is to bring the best of Lincoln to each and every transaction, ensuring the topmost outcomes for our clients.
Roderick O’Neill
Managing Director & Co-head of Healthcare
New York
